CRPC w/ Bone Metastases - Results from #160

REVIEW UroToday

Cancer Cell Colonisation in the Bone Microenvironment November 2, 2016

Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation November 2, 2016

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer November 1, 2016

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone November 1, 2016

[New progress of castration-resistant prostate cancer immunotherapy] October 3, 2016

Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer October 3, 2016

2016 ESMO Congress - Bayer to Showcase Latest Oncology Research September 28, 2016

Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy September 28, 2016

68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept September 27, 2016

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial September 12, 2016

Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC) August 31, 2016

How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer August 25, 2016

Bone Marrow Adipose Tissue: A New Player in Cancer Metastasis to Bone August 4, 2016

No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer August 4, 2016

Factors associated with improved survival following surgical treatment for metastatic prostate cancer in the spine: retrospective analysis of 29 patients in a single center August 2, 2016

Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer August 1, 2016

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial August 1, 2016

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer July 25, 2016

[Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring] July 21, 2016

Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer July 21, 2016

Page 9 of 15